Now showing items 21-30 of 51
Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma
(Wiley Subscription Services, Inc., A Wiley Company, 2003-07-15)
BACKGROUND Preclinical data suggest that the combination of intravenous (i.v.) paclitaxel, carboplatin, oral etoposide, and oral estramustine (TEEC) has significant activity in patients with advanced, hormone-refractory ...
Stromal factors involved in prostate carcinoma metastasis to bone
(Wiley Subscription Services, Inc., A Wiley Company, 2003-02-01)
BACKGROUND Prostate carcinoma (PC) frequently metastasizes to bone, where it causes significant morbidity and mortality. Stromal elements in the primary and metastatic target organs are important mediators of tumor cell ...
Hospital lymph node counts and survival after radical cystectomy The views expressed herein do not necessarily represent the views of Center for Medicare and Medicaid Services or the United States Government.
(Wiley Subscription Services, Inc., A Wiley Company, 2008-02-15)
BACKGROUND. Several studies suggest that patients in whom more lymph nodes are examined have improved survival after radical cystectomy for bladder cancer. Despite growing calls for using lymph node counts as a hospital ...
The quality of surgical pathology care for men undergoing radical prostatectomy in the U.S.
(Wiley Subscription Services, Inc., A Wiley Company, 2007-06-15)
BACKGROUND. The authors assessed adherence with the College of American Pathologists (CAP) radical prostatectomy (RP) practice protocol in a national sample of men who underwent RP for early-stage prostate cancer. METHODS. ...
PTHrP-induced MCP-1 production by human bone marrow endothelial cells and osteoblasts promotes osteoclast differentiation and prostate cancer cell proliferation and invasion in vitro
(Wiley Subscription Services, Inc., A Wiley Company, 2007-08-15)
Prostate cancer (PCa) preferentially metastasizes to bone resulting in osteoblastic lesions with underlying osteolytic activities. The mechanisms through which PCa cells promote osteolytic activities and subsequent ...
Moving beyond the “1 size fits all” paradigm See referenced original article in Cancer . 2008;112:61–68.
(Wiley Subscription Services, Inc., A Wiley Company, 2008-03)
No abstract.
Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862)
(Wiley Subscription Services, Inc., A Wiley Company, 2009-12-01)
BACKGROUND: This phase 2 trial was designed to evaluate the efficacy of vorinostat in chemotherapy-pretreated patients with metastatic castration-resistant prostate cancer. METHODS: Patients with disease progression on ...
The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer
(Wiley Subscription Services, Inc., A Wiley Company, 2006-08-01)
BACKGROUND. The objective of this study was to characterize changes in hemoglobin (HGB) levels after the initiation of androgen-deprivation therapy (ADT) in patients with previously untreated, metastatic prostate cancer ...
Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients Presented in part at the American Society of Clinical Oncology Multidisciplinary Prostate Cancer Symposium, February 17–19, 2005, Orlando, Florida; and the American Society of Clinical Oncology Multidisciplinary Prostate Cancer Symposium, February 24–26, 2006.
(Wiley Subscription Services, Inc., A Wiley Company, 2007-08-01)
BACKGROUND. This randomized, noncomparative, multicenter, clinical trial evaluated ixabepilone or mitoxantrone/prednisone (MP) as second-line chemotherapy for taxane-refractory, hormone-refractory, prostate cancer (HRPC). ...
Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin
(Wiley Subscription Services, Inc., A Wiley Company, 2008-05-15)
BACKGROUND. Many patients with invasive urothelial cell cancer are poor candidates for cisplatin-based chemotherapy, and many are high risk for cystectomy. Southwest Oncology Group Trial 8733 was designed to address ...